Opinion: NEJM sheds light on payments to doctors
It should come as no surprise that pharmaceutical companies pay doctors for a variety of reasons such as research, lecturing, and teaching. Such payments are justified as these physicians tend to be in demand as experts and their expertise is valued. They can't be expected to do this work pro bono – their time is valuable. However, such payments are viewed with great suspicion. Industry critics are quick to charge that what companies are really doing is currying favor with doctors so that they will write more prescriptions for their drugs. This type of "manipulation" is believed to be a conflict-of-interest.
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- CA Powers Up $80M HIE to 'Create Value in the Data'
- TJC Warns Hospitals of Deadly Medical Tubing Mistakes
- 3 Traits Personality Assessments Can't Reveal
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- Consumerism Drives Healthcare Branding, Rebranding Efforts